Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice
Abstract Influenza infections are often complicated by secondary bacterial infections such as MRSA pneumonia, which increase morbidity and mortality. Viral infections lead to an inflammatory response that includes elevated levels of IL‐6 and interferons. IL‐6 activates the JAK/STAT signaling pathway...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Physiological Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.14814/phy2.70232 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136488620064768 |
|---|---|
| author | Lokesh Sharma Ravineel B. Singh Caden Ngeow Rick van derGeest Alexis M. Duray Nathanial J. Tolman Bryan J. McVerry Charles S. Dela Cruz John F. Alcorn William Bain Keven M. Robinson |
| author_facet | Lokesh Sharma Ravineel B. Singh Caden Ngeow Rick van derGeest Alexis M. Duray Nathanial J. Tolman Bryan J. McVerry Charles S. Dela Cruz John F. Alcorn William Bain Keven M. Robinson |
| author_sort | Lokesh Sharma |
| collection | DOAJ |
| description | Abstract Influenza infections are often complicated by secondary bacterial infections such as MRSA pneumonia, which increase morbidity and mortality. Viral infections lead to an inflammatory response that includes elevated levels of IL‐6 and interferons. IL‐6 activates the JAK/STAT signaling pathway, amplifying downstream inflammation. Given the clinical efficacy of the JAK inhibitor baricitinib in reducing disease severity in COVID‐19, we evaluated its impact in a murine model of influenza, MRSA, and post‐influenza MRSA pneumonia. Additionally, because IL‐6 inhibitory therapies have improved outcomes during COVID‐19, we evaluated the impact of IL‐6 deletion on post‐influenza MRSA pneumonia. In our studies, baricitinib effectively inhibited the JAK/STAT pathway in the lungs, as demonstrated by decreased interferon‐stimulated genes (ISGs) and STAT3 phosphorylation. Despite this inhibition, baricitinib did not cause a global suppression of cytokines. Notably, baricitinib treatment did not impair either antiviral or antibacterial host immunity, inflammatory cell recruitment, or lung tissue injury. IL‐6 deficiency did not alter weight loss, inflammatory cell recruitment, or bacterial burden during post‐influenza MRSA pneumonia. These findings suggest that both JAK inhibition via baricitinib and IL‐6 deletion do not enhance host defense or limit tissue injury in murine models of influenza and post‐influenza MRSA pneumonia. |
| format | Article |
| id | doaj-art-5dee9d15cf4a4238af8aaf3891b53b44 |
| institution | OA Journals |
| issn | 2051-817X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Physiological Reports |
| spelling | doaj-art-5dee9d15cf4a4238af8aaf3891b53b442025-08-20T02:31:08ZengWileyPhysiological Reports2051-817X2025-02-01133n/an/a10.14814/phy2.70232Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male miceLokesh Sharma0Ravineel B. Singh1Caden Ngeow2Rick van derGeest3Alexis M. Duray4Nathanial J. Tolman5Bryan J. McVerry6Charles S. Dela Cruz7John F. Alcorn8William Bain9Keven M. Robinson10Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary Medicine, Department of Pediatrics University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary Medicine, Department of Pediatrics University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USADivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine University of Pittsburgh Pittsburgh Pennsylvania USAAbstract Influenza infections are often complicated by secondary bacterial infections such as MRSA pneumonia, which increase morbidity and mortality. Viral infections lead to an inflammatory response that includes elevated levels of IL‐6 and interferons. IL‐6 activates the JAK/STAT signaling pathway, amplifying downstream inflammation. Given the clinical efficacy of the JAK inhibitor baricitinib in reducing disease severity in COVID‐19, we evaluated its impact in a murine model of influenza, MRSA, and post‐influenza MRSA pneumonia. Additionally, because IL‐6 inhibitory therapies have improved outcomes during COVID‐19, we evaluated the impact of IL‐6 deletion on post‐influenza MRSA pneumonia. In our studies, baricitinib effectively inhibited the JAK/STAT pathway in the lungs, as demonstrated by decreased interferon‐stimulated genes (ISGs) and STAT3 phosphorylation. Despite this inhibition, baricitinib did not cause a global suppression of cytokines. Notably, baricitinib treatment did not impair either antiviral or antibacterial host immunity, inflammatory cell recruitment, or lung tissue injury. IL‐6 deficiency did not alter weight loss, inflammatory cell recruitment, or bacterial burden during post‐influenza MRSA pneumonia. These findings suggest that both JAK inhibition via baricitinib and IL‐6 deletion do not enhance host defense or limit tissue injury in murine models of influenza and post‐influenza MRSA pneumonia.https://doi.org/10.14814/phy2.70232bacteria super‐infectioninfluenzaJAK inhibitionmethicillin‐resistant staph aureus |
| spellingShingle | Lokesh Sharma Ravineel B. Singh Caden Ngeow Rick van derGeest Alexis M. Duray Nathanial J. Tolman Bryan J. McVerry Charles S. Dela Cruz John F. Alcorn William Bain Keven M. Robinson Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice Physiological Reports bacteria super‐infection influenza JAK inhibition methicillin‐resistant staph aureus |
| title | Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice |
| title_full | Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice |
| title_fullStr | Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice |
| title_full_unstemmed | Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice |
| title_short | Therapeutic JAK inhibition does not impact lung injury during viral or bacterial pneumonia in male mice |
| title_sort | therapeutic jak inhibition does not impact lung injury during viral or bacterial pneumonia in male mice |
| topic | bacteria super‐infection influenza JAK inhibition methicillin‐resistant staph aureus |
| url | https://doi.org/10.14814/phy2.70232 |
| work_keys_str_mv | AT lokeshsharma therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT ravineelbsingh therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT cadenngeow therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT rickvandergeest therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT alexismduray therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT nathanialjtolman therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT bryanjmcverry therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT charlessdelacruz therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT johnfalcorn therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT williambain therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice AT kevenmrobinson therapeuticjakinhibitiondoesnotimpactlunginjuryduringviralorbacterialpneumoniainmalemice |